You are here

Article Text

Article menu
Download PDFPDF
Drugs and Devices in COPD
P297 Lung-function profile before and after the first moderate to severe exacerbation during the wisdom study
  1. E Wouters1,
  2. H Magnussen2,
  3. R Rodriguez-Roisin3,
  4. K Tetzlaff4,
  5. S Bell5,
  6. PM A Calverley6
  1. 1Department of Respiratory Medicine, University of Maastricht, Maastricht, the Netherlands
  2. 2Pulmonary Research Institute at Lung Clinic Grosshansdorf, Airway Research Centre North, German Centre for Lung Research, Grosshansdorf, Germany
  3. 3Servei de Pneumologia, Hospital Clínic IDIBAPS-CIBERES, Universitat de Barcelona, Barcelona, Spain
  4. 4Boehringer Ingelheim Pharma GmbH and Co. KG, Ingelheim, Germany
  5. 5Department of Biometry and Data Management, Boehringer Ingelheim, Bracknell, UK
  6. 6Institute of Ageing and Chronic Disease, Aintree University Hospital, Liverpool, UK

Abstract

Rationale The WISDOM study (NCT00975195) showed no increased risk of exacerbation when inhaled corticosteroid (ICS) was withdrawn stepwise in patients with severe COPD on LAMA+LABA maintenance therapy versus continued LAMA+LABA+ICS.1 Daily home spirometry measured the time course of lung-function changes throughout the study. The aim of this post hoc analysis was to address the lung-function profile leading up to, during and following the first moderate-to-severe exacerbation.

Methods WISDOM was a multinational, randomised, double-blind study.1 Patients with severe to very severe COPD entered a 6-week run-in with LAMA+LABA+ICS (tiotropium 18 µg once daily; salmeterol 50 µg twice daily; fluticasone propionate 500 µg twice daily), and were randomised to continue LAMA+LABA+ICS or salmeterol/tiotropium for 52 weeks while discontinuing ICS in a stepwise manner over 12 weeks. On-treatment daily forced expiratory volume in 1 second (FEV1) change from baseline was calculated before and after the first moderate-to-severe exacerbation. In this post hoc analysis, we included patients who experienced a moderate-to-severe exacerbation after the ICS-withdrawal visit, did not have an exacerbation in the 8 weeks before or after the exacerbation, and had daily home-measured FEV1 data available for every week analysed.

Results Of 2488 patients, 262 experienced a moderate-to-severe exacerbation after the ICS-withdrawal visit and had lung-function data for every week. For all patients combined (ICS and ICS withdrawal), change in FEV1 remained relatively stable 56–14 days before the first moderate-to-severe exacerbation (mean FEV1 change from baseline values: −0.04 to −0.07 L) (Figure). There was a decline in lung function starting 2–3 weeks before exacerbation (FEV1 change value of −0.12 L from baseline), followed by a moderate improvement over ∼14 days. Post-exacerbation lung function did not reach pre-exacerbation levels.

Conclusions Lung function was relatively stable in both treatment groups. Home spirometry measurements showed a marked decline in FEV1 prior to moderate-to-severe exacerbation with improvements seen post-exacerbation, although not to pre-exacerbation levels. These findings support the usefulness of home spirometry to predict exacerbations and to indicate subsequent worsening of lung function resulting from a previous COPD exacerbation.

Funding Boehringer Ingelheim.

Please refer to page A273 for declarations of interest in relation to abstract P297.

Reference

  1. Magnussen H, et al. N Engl J Med 2014;371:1285–1294.

Abstract P297 Figure 1
Abstract P297 Figure 1

Mean change from baseline in on-treatment daily FEV1 before and after first moderate to severe exacerbation for both treatment combined.

https://doi.org/10.1136/thoraxjnl-2016-209333.440

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.